Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems

https://doi.org/10.1016/0168-3659(92)90014-IGet rights and content

Abstract

Design factors affecting release of octreotide and bovine serum albumin from microspheres and disk-shaped implants were studied. The polymers used were biodegradable branched poly(dl-lactide-co-glycolide-d-glucose) and linear poly (dl-lactide-co-glycolide). Octreotide, SandostatinR, is an octa-peptide analogue of somatostatin. Bovine serum albumin served as a model compound. Microspheres were produced by a modified triple-emulsion technique, implants by compression moulding. In vivo studies in rats and rabbits revealed a continuous release of octreotide from microspheres over 1–2 months. This resulted in a corresponding decrease of pituitary volume in animals with estradiol induced pituitary hyperplasia. In vitro release studies demonstrated an increased release of peptide and protein with increasing loading levels and contrary to expectation with increasing polymer molecular weights. Composition and ionic strength of the in vitro release medium affected the release behaviour. The fractional release of octreotide from microspheres decreased with increasing ionic strength of the medium. Water uptake and pore formation of implants started as early as day one of exposure to phosphate buffer and increased slowly until approximately day 15, when fragmentation and erosion of the polymer were noticeable. Polymer molecular weights decreased within the same period of time at a constant rate. It was concluded from a mechanistical point of view, that pore-diffusion and bioerosion play an important role on the release of peptides and proteins, but are insufficient to describe the sequelae of events when these systems are exposed to an aqueous environment both in vivo and in vitro. Osmotic effects, swelling of the devices and ionic interactions e.g. such between polymer terminal carboxylic acid groups and basic polypeptides have to be taken into account to explain the release properties of these delivery systems.

References (27)

  • F.G. Hutchinson et al.

    Biodegradable polymers for the sustained release of peptides

    Biochem. Soc. Trans.

    (1985)
  • Y. Ogawa et al.

    A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid

    Chem. Pharm. Bull.

    (1988)
  • M.D. Katz et al.

    Octreotide, a new somatostatin analogue

    Clin. Pharmacol.

    (1989)
  • Cited by (174)

    • Characterization and carboplatin loaded chitosan nanoparticles for the chemotherapy against breast cancer in vitro studies

      2017, International Journal of Biological Macromolecules
      Citation Excerpt :

      It is a common phenomenon, the increasing release rate with increase in loading capacity of carboplatin (drug) [42,43] and might be due to the increasing concentration gradient of the drug between the CsNPs and the release medium [41]. Furthermore, the release rate has also been depended on various conditions such as cross-linker concentration [37], the molecular weight of a polymer, particle size [36,44] charged on drugs and polymers [44,45]. We also evaluated that carboplatin release in vitro showed a rapid initial burst, followed by slow release.

    • Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics

      2015, Journal of Controlled Release
      Citation Excerpt :

      Release during this period is determined by the evolving pore network [109]. However, as the particle becomes more porous and the internal surface area increases, protein adsorption and desorption from the polymer play an important role in the release kinetics [103,110]. When surfactants which prevent protein adsorption to the polymer surface were included in the release media of PLGA particles containing BSA, a second burst was observed [111].

    View all citing articles on Scopus
    1

    Present address: Philipps-University Marburg, Dept. of Pharmaceutics, D-3550 Marburg, Germany.

    View full text